The Prevalence and Impact of Dry Eye Disease

The Prevalence and Impact of Dry Eye Disease
Media formats available:
Details
Presenters
  • Overview

    This video interview highlights the prevalence and impact of dry eye disease. The impact of this disease of these groups will be discussed: Ocular Surface Disease patients, Cataract and refractive surgery patients, Contact lens dropout patients.

    This activity is supported by unrestricted educational grants from Alcon, Avellino, Bausch + Lomb, Johnson & Johnson Vision, RVL, Santen, Sight Sciences, Tarsus, TearLab, and Thea.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Review the definition, prevalence, and impact of various ocular surface diseases within the overall population and in the following groups: Ocular Surface Disease Patients, Cataract and refractive surgery patients, Contact lens dropout patients
    • Accreditation

      Sponsored by:  

      Evolve Medical Education LLC (Evolve) is a COPE-accredited administrator. 
      This activity, COPE Activity Number 123850, is accredited by COPE for continuing education for optometrists for .25 hours.

      Course #: 78199-TD
      Activity #: 123850

    • Participation Method

      In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

    • Faculty and Disclosures

      Marc R. Bloomenstein, OD, FAAO

      Marc R. Bloomenstein, OD, FAAO

      Schwartz Laser Eye Center
      Director of Optometric Services
      Scottsdale, AZ


      Cecelia C. Koetting, OD, FAAO

      Cecelia C. Koetting, OD, FAAO

      Hines Sight
      Denver, CO


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

      The following faculty/staff members have the following financial relationships with ineligible companies.

      Marc R. Bloomenstein, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Allergan, Azura, Bausch + Lomb, Johnson & Johnson Vision, Kala Pharmaceuticals, OcuSoft, Sight Sciences, Sun Pharmaceutical Industries, and Tarsus. Grant/Research Support: Sight Sciences. Speaker’s Bureau: Allergan, Bausch + Lomb, Johnson & Johnson Vision, Kala Pharmaceuticals, OysterPoint, RVL, Sight Sciences, and Sun Pharmaceutical Industries.

      Cecelia C. Koetting, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Grant/Research: Johnson & Johnson Vision. Consultant: Alcon, Allergan, Bruder, Dompé, Eyevance, Glaukos, Kala Pharmaceuticals, Ivantis, Orasis, OysterPoint, RVL, Tarsus, and Visus. Speaker's Bureau: Alcon, Dompé, Eyevance, Ivantis, OysterPoint, and RVL. 

      The Evolve and The Fundingsland Group staff and planners have no financial relationships with ineligible companies.

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Alcon, Avellino, Bausch + Lomb, Johnson & Johnson Vision, RVL, Santen, Sight Sciences, Tarsus, TearLab, or Thea.

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Release Date:

      Expiration Date:

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    Register

    We're glad to see you're enjoying Evolve Medical Education…
    but how about a more personalized experience?

    Register for free